SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-Aravive Reports Q4 2020 Financial Results

· 03/16/2021 07:16
BRIEF-Aravive Reports Q4 2020 Financial Results

- Aravive Inc ARAV.O:

  • Q4 LOSS PER SHARE $0.25

  • ARAVIVE - FIRST PATIENT DOSED IN PHASE 1B/2 TRIAL OF AVB-500 IN CLEAR CELL RENAL CELL CARCINOMA IN 1Q 2021; ON-TRACK TO REPORT TOPLINE DATA IN 2H 2021

  • Q4 EARNINGS PER SHARE VIEW $-0.52 -- REFINITIV IBES DATA

Source text for Eikon: ID:nGNX1wlYcC

Further company coverage: ARAV.O


((Reuters.Briefs@thomsonreuters.com;))